Press Release: Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System

Dramatically thinner scaffold combines excellent deliverability and conformability with DESolve's market-leading clinical benefits.

Elixir Medical Corp.

News Well, Regulatory/Clearance, Bioabsorbable Stents, CE Mark

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1v9dpFB